(Adnkronos Health) – The results of Meporeal are part of a context of progressive evolution of therapeutic objectives in CRSwNP, the note recalls. Alongside the reduction of the endoscopic nasal polyp score and the improvement of symptoms, the possibility of achieving comprehensive and lasting control of the disease is gaining increasing importance, to the point of considering the path towards clinical remission under treatment as an increasingly achievable goal. In this scenario, real-world evidence takes on particular value, integrating the results of registrational clinical studies, allowing the observation of treatment outcomes in daily clinical practice, in broader populations.
Meporeal – it reads – contributes to this evolution by offering a snapshot of the treatment response in daily clinical practice: alongside the improvements observed in clinical parameters and quality of life, the study allows for a deeper understanding of achieving disease control, the path towards remission, and the needs that persist even after treatment. One of Meporeal’s distinctive elements is its multicenter dimension. The study was carried out thanks to the collaboration of 25 Italian specialist centers that contributed to the collection and analysis of evidence from clinical practice. The involvement of a wide network of centers allowed for the collection of data related to patients with different therapeutic paths, offering a detailed picture of CRSwNP management in our country.
“For over 50 years, GSK has been committed to the area of respiratory diseases, with scientific research and innovation at the heart of its journey. In these years, we have contributed to the evolution of knowledge and therapeutic options, with the aim of addressing the unmet needs of people living with chronic respiratory and inflammatory diseases. Evidence such as that emerged from the Meporeal study confirms how important it is to continue to deepen the understanding of these pathologies, also through data collected in daily clinical practice. As GSK, we strongly believe in the value of collaboration with the scientific community and in the importance of supporting a research ecosystem capable of translating new knowledge into concrete prospects for patients,” declares Maria Sofia Rosati, Medical Director of GSK Italy.